ストックスクリーナーアプリを入手
12.89
1.64%
-0.21
前日終値:
$13.10
開ける：
$13.11
24時間の取引高:
329.66K
Relative Volume:
0.50
時価総額：
$704.30M
収益：
$8.78M
当期純損益:
$-104.70M
株価収益率:
-5.4388
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
+4.67%
1か月 パフォーマンス:
+10.79%
6か月 パフォーマンス:
+31.21%
1年 パフォーマンス:
-18.76%
1日の値動き範囲:
$12.79
$13.22
1週間の範囲:
$12.55
$14.78
52週間の値動き範囲:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
STOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
12.90 | 715.22M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.86 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.98 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.90 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.47 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.75 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Earnings Report Alerts For Every Investor - jammulinksnews.com
How strong is Stoke Therapeutics Inc. company’s balance sheetUnlock exclusive investment alerts - jammulinksnews.com
Is it the right time to buy Stoke Therapeutics Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
How volatile is Stoke Therapeutics Inc. stock compared to the marketSuperior return velocity - jammulinksnews.com
What are analysts’ price targets for Stoke Therapeutics Inc. in the next 12 monthsDiscover market opportunities others miss - jammulinksnews.com
How does Stoke Therapeutics Inc. generate profit in a changing economyInvest smarter with actionable market insights - jammulinksnews.com
When is Stoke Therapeutics Inc. stock expected to show significant growthGet daily updates on top-performing stocks - jammulinksnews.com
How does Stoke Therapeutics Inc. compare to its industry peersBreakout profit opportunities - jammulinksnews.com
Stoke Therapeutics Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - PrintWeekIndia
Is Stoke Therapeutics Inc. a good long term investmentSuperior return velocity - Autocar Professional
What analysts say about Stoke Therapeutics Inc. stockExtraordinary market timing - Autocar Professional
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize
Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest
What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Published on: 2025-07-22 15:57:09 - jammulinksnews.com
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
Stoke Therapeutics Inc (STOK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LEVIN ARTHUR A | Director |
Jun 30 '25 |
Option Exercise |
0.00 |
1,210 |
0 |
2,420 |
0.49%
1.21%
大文字化:
|
ボリューム (24 時間):